Top

Published in:

Open Access 01-12-2008 | Research article

Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy

Authors: Chel Hun Choi, Sang Yong Song, Jung-Joo Choi, Young Ae Park, Heeseok Kang, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Je-Ho Lee, Duk-Soo Bae

Published in: BMC Cancer | Issue 1/2008

Abstract

Background

The prediction of response to treatment would be valuable for managing cervical carcinoma with neoadjuvant chemotherapy.

Methods

To this end, the expression of VEGF was analyzed by immunohistochemistry using paraffin-embedded pre-treatment cervical biopsy tissues. This study included 29 patients with bulky IB to IIA cervical squamous cell carcinoma treated with neoadjuvant chemotherapy.

Results

Fifteen (51.7%) of 29 patients were scored as VEGF-positive. Response to chemotherapy (complete response or residual tumor with less than 3 mm stromal invasion) was observed in eight patients (27.6%), and it was negatively associated with VEGF expression (P = 0.009). With logistic regression analysis, VEGF positivity continued to be an independent predictor for poor response (P = 0.032). In addition, the progression-free survival rate was significantly lower in patients with VEGF-positive tumors (P = 0.033).

Conclusion

Pretreatment assessment of VEGF expression may provide additional information for identification of patients with cervical cancer who had a low likelihood of response to neoadjuvant chemotherapy and an unfavorable prognosis.

Available only for authorised users

Thomas GM: Improved treatment for cervical cancer – concurrent chemotherapy and radiotherapy. N Engl J Med. 1999, 340 (15): 1198-1200. 10.1056/NEJM199904153401509.CrossRefPubMed

Pignata S, Silvestro G, Ferrari E, Selvaggi L, Perrone F, Maffeo A, Frezza P, Di Vagno G, Casella G, Ricchi P, et al: Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix. J Clin Oncol. 1999, 17 (3): 756-760.PubMed

Serur E, Mathews RP, Gates J, Levine P, Maiman M, Remy JC: Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix. Gynecol Oncol. 1997, 65 (2): 348-356. 10.1006/gyno.1997.4645.CrossRefPubMed

Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol. 1995, 26 (1): 86-91. 10.1016/0046-8177(95)90119-1.CrossRefPubMed

Fine BA, Valente PT, Feinstein GI, Dey T: VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol Oncol. 2000, 76 (1): 33-39. 10.1006/gyno.1999.5658.CrossRefPubMed

Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K: High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000, 88 (10): 2239-2245. 10.1002/(SICI)1097-0142(20000515)88:10<2239::AID-CNCR6>3.0.CO;2-V.CrossRefPubMed

Cheng WF, Chen CA, Lee CN, Chen TM, Hsieh FJ, Hsieh CY: Vascular endothelial growth factor in cervical carcinoma. Obstet Gynecol. 1999, 93 (5 Pt 1): 761-765. 10.1016/S0029-7844(98)00505-5.PubMed

Cheng WF, Chen CA, Lee CN, Wei LH, Hsieh FJ, Hsieh CY: Vascular endothelial growth factor and prognosis of cervical carcinoma. Obstet Gynecol. 2000, 96 (5 Pt 1): 721-726. 10.1016/S0029-7844(00)01025-5.PubMed

Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM: Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer. 2000, 83 (5): 620-625. 10.1054/bjoc.2000.1319.CrossRefPubMedPubMedCentral

10.

Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60 (2): 203-212.PubMed

11.

Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS: Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol. 2007, 104 (1): 64-69. 10.1016/j.ygyno.2006.07.006.CrossRefPubMed

12.

Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A, Malzoni C, et al: Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J Clin Oncol. 2005, 23 (18): 4137-4145. 10.1200/JCO.2005.04.172.CrossRefPubMed

13.

Ribeiro U, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ, Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC: p53 sequence analysis predicts treatment response and outcome of patients with esophageal carcinoma. Cancer. 1998, 83 (1): 7-18. 10.1002/(SICI)1097-0142(19980701)83:1<7::AID-CNCR2>3.0.CO;2-R.CrossRefPubMed

14.

Kimura S, Kitadai Y, Tanaka S, Kuwai T, Hihara J, Yoshida K, Toge T, Chayama K: Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer. 2004, 40 (12): 1904-1912. 10.1016/j.ejca.2004.04.035.CrossRefPubMed

15.

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS: Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000, 105 (8): R15-24. 10.1172/JCI8829.CrossRefPubMedPubMedCentral

16.

Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, Radaelli U, Di Bacco A, Guglielmi RB, Bevilacqua P: Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer. 1996, 69 (3): 205-211. 10.1002/(SICI)1097-0215(19960621)69:3<205::AID-IJC10>3.0.CO;2-6.CrossRefPubMed

17.

Raspollini MR, Amunni G, Villanucci A, Baroni G, Boddi V, Taddei GL: Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer. 2004, 14 (5): 815-823. 10.1111/j.1048-891X.2004.014514.x.CrossRefPubMed

18.

Baish JW, Jain RK: Fractals and cancer. Cancer Res. 2000, 60 (14): 3683-3688.PubMed

19.

Jain RK: The next frontier of molecular medicine: delivery of therapeutics. Nat Med. 1998, 4 (6): 655-657. 10.1038/nm0698-655.CrossRefPubMed

20.

Piret JP, Mottet D, Raes M, Michiels C: Is HIF-1alpha a pro- or an anti-apoptotic protein?. Biochem Pharmacol. 2002, 64 (5–6): 889-892. 10.1016/S0006-2952(02)01155-3.CrossRefPubMed

21.

Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, Millard P, Fuggle S, Harris AL: Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002, 62 (9): 2493-2497.PubMed

22.

Tjalma W, Weyler J, Weyn B, Van Marck E, Van Daele A, Van Dam P, Goovaerts G, Buytaert P: The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol. 2000, 92 (2): 251-257. 10.1016/S0301-2115(99)00295-X.CrossRefPubMed

23.

Jain RK: The Eugene M. Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 1997, 4 (1): 1-23. 10.3109/10739689709148314.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/8/295/prepub

Title: Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy
Authors: Chel Hun Choi
Sang Yong Song
Jung-Joo Choi
Young Ae Park
Heeseok Kang
Tae-Joong Kim
Jeong-Won Lee
Byoung-Gie Kim
Je-Ho Lee
Duk-Soo Bae
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2008
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/1471-2407-8-295

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Nestin expression in osteosarcomas and derivation of nestin/CD133 positive osteosarcoma cell lines

Validation of putative reference genes for gene expression studies in human hepatocellular carcinoma using real-time quantitative RT-PCR

Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study

Histological subtype of lung cancer in relation to socio-economic deprivation in South East England

Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis

Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples

Keynote webinar | Spotlight on antibody–drug conjugates in cancer